Lind L, Wengle B, Lithell H, Ljunghall S
Department of Internal Medicine, Uppsala University Hospital, Sweden.
Ups J Med Sci. 1991;96(3):199-204. doi: 10.3109/03009739109179271.
A hypotensive effect of active vitamin D treatment (alphacalcidol 1 mg daily) has previously been reported in three double-blind, placebo-controlled studies over 4-6 months in subjects with mild primary hyperparathyroidism (HPT), intermittent hypercalcemia and essential hypertension. The commonly used antihypertensive drugs, thiazides and betablockers, both induce impairments in both glucose and lipid metabolism and the thiazides are known to cause an elevation of serum urate. The effects of vitamin D treatment on these metabolic variables were recorded in these studies. Alphacalcidol did not induce any changes in fasting glucose HbA1c or insulin, serum triglycerides, cholesterol or serum urate in any of the treated groups. Neither was HDL cholesterol affected, except for a rise seen in the HPT subjects. It is therefore concluded that no major metabolic alterations in glucose or lipid metabolism or serum urate accompany the hypotensive effect of vitamin D.
先前有三项双盲、安慰剂对照研究报道，对于轻度原发性甲状旁腺功能亢进（HPT）、间歇性高钙血症和原发性高血压患者，在4至6个月的时间里，活性维生素D治疗（每日1毫克阿法骨化醇）具有降压作用。常用的降压药，噻嗪类药物和β受体阻滞剂，都会导致葡萄糖和脂质代谢受损，并且已知噻嗪类药物会导致血清尿酸升高。这些研究记录了维生素D治疗对这些代谢变量的影响。在任何治疗组中，阿法骨化醇均未引起空腹血糖、糖化血红蛋白（HbA1c）或胰岛素、血清甘油三酯、胆固醇或血清尿酸的任何变化。除了HPT患者中观察到的HDL胆固醇升高外，HDL胆固醇也未受影响。因此得出结论，维生素D的降压作用不会伴随葡萄糖或脂质代谢或血清尿酸的重大代谢改变。
